The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA2

Energy Intake and Plasma Adiponectin as Potential Determinants of Lipoprotein‐Associated Phospholipase A2 Activity: A Cross‐Sectional Study

“…No significant differences were observed across Lp‐PLA 2 activity quartiles with reference to history of dyslipidemia or hypertension. Our results are in agreement with previous studies among overweight and obese subjects (Jackisch et al, ; Steffen et al, ), subjects with dyslipidemia (Tellis et al, ) and apparently healthy subjects with prehypertension (Kim et al, ). Higher Lp‐PLA 2 activity could be explained by higher Lp‐PLA 2 mass concurrently with higher levels of total and LDL‐cholesterol, triacylglycerols, and apolipoprotein B in obese compared to nonobese subjects and in subjects with dyslipidemia compared to subjects with normal lipid levels (Barakat et al, ; Jackisch et al, ; Tellis et al, ).…”

“…No significant differences were observed across Lp-PLA 2 activity quartiles with reference to history of dyslipidemia or hypertension. Our results are in agreement with previous studies among overweight and obese subjects (Jackisch et al, 2018;Steffen et al, 2013), subjects with dyslipidemia (Tellis et al, 2013) and apparently healthy subjects with prehypertension (Kim et al, 2014a). Higher Lp- 6.3 (5.3-8.4) 6.2 (5.4-7.5) 6.4 (5.7-6.9) 6.5 (5.7-7.7) 0.555 MUFA-to-SFA ratio 1.7 (1.5-2.1) 1.7 (1.5-1.9) 1.7 (1.4-1.9) 1.…”

“…Higher Lp- 6.3 (5.3-8.4) 6.2 (5.4-7.5) 6.4 (5.7-6.9) 6.5 (5.7-7.7) 0.555 MUFA-to-SFA ratio 1.7 (1.5-2.1) 1.7 (1.5-1.9) 1.7 (1.4-1.9) 1. PLA 2 activity could be explained by higher Lp-PLA 2 mass concurrently with higher levels of total and LDL-cholesterol, triacylglycerols, and apolipoprotein B in obese compared to nonobese subjects and in subjects with dyslipidemia compared to subjects with normal lipid levels (Barakat et al, 2017;Jackisch et al, 2018;Tellis et al, 2013).…”

The correlation between lipoprotein associated phospholipase A2 and central overweight status

“…Lp-PLA 2 (lipoprotein-associated phospholipase A 2 ) catalyzes the hydrolysis of acetyl ester at the sn-2 position of platelet-activating factor (PAF), 6 also known as platelet-activating factor acetylhydrolase (PAF-AH). It is a calcium‐independent serine lipase produced predominantly by the macrophages, monocytes, T lymphocyte, and mast cells, which circulates by binding mainly to apolipoprotein B (apo B), 7 with the low-density lipoprotein (LDL) (80%) and high-density lipoprotein (HDL) (20%), 8 could independently predict cardiovascular risk. 9 Since Lp-PLA 2 activity is positively associated with LDL and adiposity 10 that helps predict the risk of atherosclerosis and cardiovascular disease.…”

Research update for articles published in EJCI in 2012

“…We measured apoB‐Lp‐PLA2, which also decreased after sodium loading . More recently, apoB‐Lp‐PLA2 was found to be elevated in hypercholesterolaemia and its change after statin treatment correlated with changes in oxidized low‐density lipoproteins . ApoB‐Lp‐PLA2 may represent a pathophysiologically relevant metric of the atherogenic potential of apoB‐lipoproteins.…”